Description: BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
Home Page: www.bioinvent.com
The Gamma Building
Lund,
223 70
Sweden
Phone:
46 4 62 86 85 50
Officers
| Name | Title |
|---|---|
| Dr. Martin Welschof Ph.D. | President & CEO |
| Mr. Stefan Ericsson M.B.A. | Chief Financial Officer |
| Ms. Marie Moores M.Sc., R.G.N. | Chief Operating Officer |
| Mr. Kristoffer Rudenholm Hansson | Senior Vice President of Technical Operations |
| Mr. Björn Frendéus | Chief Scientific Officer |
| Ms. Cecilia Hofvander | Senior Director of Investor Relations |
| Dr. Andres McAllister | Chief Medical Officer |
| Ms. Ingrid Teige | Head of Preclinical Research |
| Ms. Sylvie Ryckebusch | Chief Business Officer |
| Dr. Ingunn Munch Lindvig | Senior Vice President of Regulatory Affairs |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8461 |
| Price-to-Sales TTM: | 6.5061 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 115 |